Scope of the Study
Vaginal rings or V-ring (polymeric drug) are the devices which are placed inside the vagina and provide continuous doses of estrogen and progestogen into the bloodstream to prevent pregnancy. V rings also have non-contraceptive applications such as symptomatic relief during menopause and management of hormonal imbalance in individuals with polycystic ovary syndrome (PCOS). Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Further, the rising prevalence of disease related to women’s health and increasing initiatives of the government to support women’s health is driving the vaginal ring market.
The market study is being classified by Type (Estring, Femring and NuvaRing), by Application (Contraception, Menopause Vasomotor Symptoms, Polycystic Ovarian Syndrome (PCOs) and Others) and major geographies with country level break-up. According to AMA, the Global Vaginal Ring market is expected to see growth rate of 2.98%
Bayer AG (Germany), Merck & Co., Inc. (United States), Ansell (Australia), Pfizer Inc. (United States), Actavis (United States), Allergan plc (Ireland), HRA Pharma SA (France), Eurogine (Spain), Yantai JiShengYaoXie (China), TianYi (China), Merck & Co., Inc (United States), Johnson & Johnson (United States) and QPharma AB (Sweden ) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are SMB Corporation of India (India), Shenyang Liren (China), H & J Medical (United States) and Novo Nordisk Ltd (India).
The Global Vaginal Ring market is moderately fragmented with companies focusing on following several marketing strategies for creating awareness among the consumers about the several advantages of vaginal rings. Several leading brands have increased their marketing expenditure for maintaining their leading positions in the market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Vaginal Ring market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Vaginal Ring market by Type, Application and Region.
On the basis of geography, the market of Vaginal Ring has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Retail Pharmacies will boost the Vaginal Ring market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Age 20-24 will boost the Vaginal Ring market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Importance of Family Planning
- Rising Prevalence of Disease Related to Women’s Health
- Increasing Progressive Outlook on Premarital Sex
- Increasing Awareness among Women Regarding use of Contraceptives Leading to Increase in End-users
- Growing Healthcare Industry and Increasing Population of Geriatric Women Population
- Probability of Developing Breast Cancer by the use of Vaginal Ring among Women
- Increasing Investment by the Government to Enhance Healthcare Facilities
- Adverse Reaction of Vaginal Rings among Some Female Population
In January 2019, clinical trial study conducted by Medical press company The Phase I study, known as MTN-038, is being conducted by researchers from the National Institutes of Health-funded Microbicide Trials Network (MTN) at three United States. Trial sites. The vaginal ring being evaluated in the study contains an antiretroviral (ARV) drug called Tenofovir, a mainstay drug used in the treatment of HIV.
In August 2018, The Food and Drug Administration approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year. Annovera is a reusable donut-shaped (ring), non-biodegradable, a flexible vaginal system that is placed in the vagina for three weeks followed by one week out of the vagina, at which time women may experience a period (a withdrawal bleed). This schedule is repeated every four weeks for one year (thirteen 28-day menstrual cycles).
Key Target Audience
Vaginal Ring Manufacturers, Healthcare Industry, Potential Investors, Government & Regulatory Bodies, Pharmaceutical Companies and Others
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase